330233
Clinical outcomes, emotional management, and medicine adherence among HIV patients in China
Method: The data was collected by 6-month follow-up survey of a longitudinal RCT initiated in 2013 among 796 HIV-positive parents in Guangxi, China. A total of 447 participants receiving ART completed the survey including demographics, mental health, and medicine adherence. The clinical outcomes were retrieved from medical records after consents. Participants who took ART medicine as prescribed at least 27 days in past 30 days were categorized as high adherence group, otherwise they were in low adherence group. Descriptive analysis and GLM were employed in data analysis.
Results: The multivariate test indicated that ART adherence was significantly associated with clinical outcomes and emotional management (F=14.367, p<.001). Univariate tests suggested that medicine adherence was positively associated with CD4 (F=18.353, p<.001), negatively associated with virus loading (F=24.903, p<.001), and negatively associated with emotional management difficulties (F=6.301, p=.012).
Discussion: Our findings confirm that self-reported ART adherence could be highly consistent with clinical outcomes among HIV patients in China. It is rarely explored but notable that emotional management problems may be a barrier to ART adherence for HIV patients. In the era when HIV/AIDS has been transforming from fatal disease to chronic one, emotional management could be a necessary component for patients’ self-management and self-care.
Learning Areas:
Social and behavioral sciencesLearning Objectives:
Demonstrate the relationships between clinical outcomes, emotional management and medicine adherence among HIV patients in China.
Keyword(s): Mental Health, Adherence
Qualified on the content I am responsible for because: I have performed the data analysis and written the abstract
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.